Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hindustan Bio Sciences Ltd's board, meeting on January 31, 2026, approved the unaudited financial results for Q3 FY26 (quarter ended December 31, 2025) along with the Limited Review Report. Revenue from operations for the quarter stood at Rs. 38.25 lakhs, up sharply from nil in Q3 FY25, while total revenue was Rs. 40.03 lakhs. The company swung to a profit after tax of Rs. 8.20 lakhs compared to a loss of Rs. 4.14 lakhs in the same quarter last year, with EPS of Rs. 0.08 versus Rs. (0.04). For the nine months ended December 2025, the company reported a small profit of Rs. 3.74 lakhs versus a loss of Rs. 0.98 lakhs in the prior year period. The auditor (VASG & Associates) issued an unqualified review report with no qualifications or adverse remarks.
This is a positive development for shareholders as the company moved from a loss-making position to profitability, driven by a sharp revival in operating revenue. However, the absolute scale remains very small (single-digit lakhs of profit), and reserves remain negative at Rs. (114.52) lakhs, so the turnaround is early-stage and investors should watch for sustained revenue traction.